Navigation Links
Quantros Patient Safety Center Receives Certification as a Patient Safety Organization (PSO)

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Quantros, a leading provider of safety, quality, and compliance solutions for the healthcare industry, today announced that the Agency for Healthcare Research and Quality (AHRQ) has granted initial certification to Quantros Patient Safety Center as a Patient Safety Organization (PSO). The listing can be viewed at The Quantros Patient Safety Center is a new division within Quantros that is specifically focused on review of safety processes, data analytics, and provision of associated knowledge content and complementary services to support healthcare providers using Quantros as a PSO to better address patient safety. Supporting healthcare providers in the improvement of safety and quality initiatives is in complete alignment with the mission and goals of the organization for more than nine years. Today more than 2,000 healthcare providers use one or more Quantros solutions for improving safety and quality within their care environment.

In addition to the Quantros Patient Safety Center, Quantros also supports other entities acting as a PSO with Quantros Patient Safety Organization (PSO) Manager, a streamlined, Web-based application that will enable PSOs to seamlessly aggregate required Common Format (CM) for event data as well as additional safety data for use as a confidential Patient Safety Work Product (PSWP). Just as with The Joint Commission ORYX Core Measures program, Quantros has chosen to act as both a technology provider and a PSO.

Dr. Sanjaya Kumar, Quantros President and CEO commented, "Quantros is in business to assist healthcare providers in advancing safety and quality improvement initiatives. The Quantros Patient Safety Center was created to further that cause for healthcare providers who want to leverage both Quantros and associated partner expertise. In addition, PSO vendors utilizing Quantros PSO Manager can avail of the services and content infrastructure and make that available to their members."

The Quantros Patient Safety Center will provide complete support per the PSO regulations including the aggregation, protection and dissemination of information including submissions and comparative reports via the Network of Patient Safety Databases (NPSD) as well as the aggregated, PHI de-identified Quantros Patient Safety Center data repository. This new division will provide a host of clinically-based services and analysis specifically designed for improving safety within the healthcare environment.

Additional information concerning the Quantros Patient Safety Center can be viewed at

About Quantros

Quantros provides real-time solutions for safety and risk management, outcomes and performance monitoring, accreditation and compliance, and surveillance and decision support for leading healthcare providers throughout the nation. Quantros' web delivered applications provide a standard platform that creates actionable knowledge that helps its clients save lives, improve quality, and conserve assets. Through a variety of direct sales and vendor partners, more than 2,000 healthcare facilities use Quantros' web-based technology solutions every day.

Quantros team members include physicians, nurses and healthcare professionals as well as an experienced team of information technology specialists. Visit Quantros on the web at

SOURCE Quantros
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quantros Launches Patient Safety Organization Manager to Streamline PSO Data Management and Submission to the Network of Patient Safety Databases
2. Quantros Expanding Support for Alternative Web Browsers
3. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
4. Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
5. Electronic Prescribing Saves Patients Money
6. Confusing risk information may lead breast cancer patients to make poor treatment choices
7. Marital problems lead to poorer outcomes for breast cancer patients
8. Vitamin B1 could reverse early-stage kidney disease in diabetes patients
9. Lenalidomide safe as single therapy for elderly CLL patients
10. Dieticians & Nutritionists Concerned Economic Downturn Will Effect Patient Health and Diets.
11. CHOC Childrens Draws First Patient Dose With RIVA System
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology: